Increased circulation of influenza A(H1N1)pdm09 viruses with reduced susceptibility to oseltamivir, Germany 2024-2026.
BACKGROUND Oseltamivir is still considered to be the first-line antiviral treatment for severe seasonal influenza. However, resistance to neuraminidase (NA) inhibitors poses significant challenges to influenza management. Since the 2023/24 season, A(H1N1)pdm09 viruses carrying neuraminidase substitutions (NA-I223V and/...